In thromboinflammation, early tissue plasminogen activator administration directly improves endothelial barrier function, prophylactic defibrotide and enoxaparin suppress microvascular thromboinflammation through endothelium-mediated mechanisms and combining enoxaparin with crizanlizumab reduces microvascular occlusion and protects endothelial function in sickle cell disease.
- Yongzhi Qiu
- Jessica Lin
- Wilbur A. Lam
